Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21112930 | 0.91 | TYMP (0.43) | MAOBXDHTDP1SLC22A1SYNJ2 | |
| SCHEMBL28290744 | 0.89 | SYNJ2 (0.42) | MAOBXDHSLC22A1SYNJ2TYMP | |
| SCHEMBL23488254 | 0.88 | CHRNB2 (0.45) | MAOBXDHTDP1SYNJ2TYMP | |
| SCHEMBL21112978 | 0.87 | SMN1; SMN2 (0.41) | MAOBTDP1SMN1; SMN2SLC22A1CYP3A4 | |
| SCHEMBL23488147 | 0.84 | SMN1; SMN2 (0.47) | MAOBXDHSMN1; SMN2SLC22A1SYNJ2 | |
| SCHEMBL21112895 | 0.84 | TDP1 (0.50) | MAOBXDHTDP1SMN1; SMN2SLC22A1 | |
| SCHEMBL23488275 | 0.82 | TYMP (0.39) | MAOBXDHTDP1TYMPCYP3A4 | |
| SCHEMBL21112887 | 0.81 | SMN1; SMN2 (0.50) | MAOBTDP1SMN1; SMN2SLC22A1ALDH1A1 | |
| SCHEMBL16018720 | 0.79 | LGALS3 (0.45) | SYNJ2TYMPCYP2C9ALDH1A1 | |
| SCHEMBL27464799 | 0.79 | PTPN1 (0.47) | MAOBCYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | SANOFI (FR) | 2021-08-17 | — | — | US | disclosed |
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | SANOFI (FR) | 2021-08-17 | — | — | US | disclosed |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2019-07-11 | — | — | US | disclosed |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2019-07-11 | — | — | US | disclosed |
| CN-109562185-A | Novel conjugates of agents and moieties capable of binding to glucose-sensing proteins | 赛诺菲 | 2019-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | GPR119, SLC2A8, SLC2A4 | MAOB 3806/4885XDH 2871/4885TDP1 4001/4885 |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | MAOB 3806/4885XDH 2871/4885TDP1 4001/4885 |
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | MAOB 3806/4885XDH 2871/4885TDP1 4001/4885 |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | MAOB 3806/4885XDH 2871/4885TDP1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.